Enrico Heffler, ERS 2018 – Corticosteroid-adverse events: a comorbidity of severe asthma?
Editorial board member Enrico Heffler (Humanitas University, Milan, Italy) considers the increasing evidence that both oral and inhaled corticosteroids can lead, particularly in severe asthmatics, to adverse events that have a significant impact on both patients quality of life and health-related costs.
Questions
Part 1
1. What proportion of patients with asthma are classified as having severe disease? (0:12)
2. What adverse effects are associated with the use of oral and inhaled corticosteroids in patients with severe asthma? (2:19)
Part 2
1. What are the impact of these adverse effects in terms of patient quality of life and overall expense? (0:12)
2. What effective strategies may be used to minimise the use of corticosteroids in these patients? (2:01)
3. What new treatment strategies are emerging for patients with severe asthma? (3:14)
Speaker disclosure: Enrico Heffler has nothing to disclose in relation to this video interview.
Filmed at the European Respiratory Society (ERS) International Congress 2018, Paris, France, September 2018.
